Home » Stocks » AGTC

Applied Genetic Technologies Corporation (AGTC)

Stock Price: $3.81 USD -0.08 (-2.06%)
Updated May 10, 2021 4:00 PM EDT - Market closed
After-hours: $3.77 -0.04 (-1.05%) May 10, 5:01 PM
Market Cap 162.03M
Revenue (ttm) n/a
Net Income (ttm) -56.53M
Shares Out 25.88M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $3.81
Previous Close $3.89
Change ($) -0.08
Change (%) -2.06%
Day's Open 3.89
Day's Range 3.67 - 3.91
Day's Volume 780,538
52-Week Range 3.54 - 9.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

It's time to take another look at penny stocks that are popular on Reddit as we dive into those getting the most attention on Thursday. The post 5 Reddit Penny Stocks Seeing the Most Chatter Thursday ap...

Other stocks mentioned: AMC, PRPO, RIOT, SOS
4 days ago - InvestorPlace

Applied Genetic Technologies Corporation (NASDAQ: AGTC) has announced additional data from the ongoing X-linked retinitis pigmentosa (XLRP) gene therapy Phase 1/2 trial, including 12-month data from Gro...

4 days ago - Benzinga

-Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials-

4 days ago - GlobeNewsWire

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associ...

5 days ago - GlobeNewsWire

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associ...

6 days ago - GlobeNewsWire

-Company remains on track to present additional 12-month data from the XLRP and achromatopsia clinical trials in the second quarter of 2021-

1 week ago - GlobeNewsWire

GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-asso...

1 week ago - GlobeNewsWire

GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-asso...

2 weeks ago - GlobeNewsWire

- AGTC Transfers Clinical Trial Materials and Phase 1/2 Data To TeamedON -

3 weeks ago - GlobeNewsWire

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-asso...

1 month ago - GlobeNewsWire

-AGTC's deep commitment to the patient voice drives solutions to support patient access to information and to improve the experience of patients participating in clinical trials-

1 month ago - GlobeNewsWire

-AGTC will highlight the value of the patient voice in gene therapy development-

1 month ago - GlobeNewsWire

Getting a big headache watching large-cap S&P 500 stocks lose steam? Small-cap stocks are giving investors a new way to make big money.

Other stocks mentioned: ATOM, AYTU, CODX, CRTX, DVAX, SRNE
2 months ago - Investors Business Daily

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-asso...

2 months ago - GlobeNewsWire

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-assoc...

2 months ago - GlobeNewsWire

-AGTC executives will address critical success factors in gene therapy manufacturing and the value of the patient perspective in gene therapy development ---- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb...

2 months ago - GlobeNewsWire

- Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022 -

2 months ago - GlobeNewsWire

Article reflects Company's leadership and innovation in scalable, reproducible manufacture of adeno-associated virus (AAV)-based gene therapies

3 months ago - GlobeNewsWire

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-assoc...

3 months ago - GlobeNewsWire

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-asso...

3 months ago - GlobeNewsWire

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-asso...

3 months ago - GlobeNewsWire

-Preliminary results suggest sustained improvements to 12-months in visual sensitivity, as measured by full field static perimetry, supported in some patients by other endpoints- -Company plans longer t...

3 months ago - GlobeNewsWire

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (A...

4 months ago - GlobeNewsWire

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -17.65% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for...

5 months ago - Zacks Investment Research

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-assoc...

5 months ago - GlobeNewsWire

- Durable improvements observed in visual sensitivity and visual acuity over a wide dose-range with a favorable safety profile -

5 months ago - GlobeNewsWire

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-assoc...

6 months ago - GlobeNewsWire

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (...

6 months ago - GlobeNewsWire

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (A...

7 months ago - GlobeNewsWire

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC), Blueprint Genetics, and Foundation Fighting Blindness, announce today that AGT...

7 months ago - GlobeNewsWire

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

- Planned Phase 2/3 trial expected to include approximately 60 patients and a responder analysis based on at least 7 decibel improvement in visual sensitivity in at least 5 loci across two active dose g...

8 months ago - GlobeNewsWire

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated viru...

8 months ago - GlobeNewsWire

Preclinical studies validate the transgene and dosing used in the ongoing Phase 1/2 clinical trial in patients with XLRP due to mutations in the RPGR gene Preclinical studies validate the transgene and ...

8 months ago - GlobeNewsWire

Patient Advisory Council to include advocates from the inherited retinal diseases global community

8 months ago - GlobeNewsWire

Washington D.C--(Newsfile Corp. - August 4, 2020) - At today’s meeting of the Small Business Capital Formation Advisory Committee, the Securities and Exchange Commission announced the appointment of two...

9 months ago - Newsfile Corp

Does Applied Genetic Technologies (AGTC) have what it takes to be a top stock pick for momentum investors? Let's find out.

10 months ago - Zacks Investment Research

Is (AGTC) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

Applied Genetic (AGTC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-as...

10 months ago - GlobeNewsWire

Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials

10 months ago - GlobeNewsWire

GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-as...

10 months ago - GlobeNewsWire

Mobile vision testing unit enables X-linked retinitis pigmentosa and achromatopsia clinical trial patients to maintain important scheduled study assessments during COVID-19 pandemic

10 months ago - GlobeNewsWire

If you’re looking to hedge your portfolio to protect some downside, or make some bets against high valuations, our deep learning algorithms have paired with our Artificial Intelligence (“AI”) technology...

Other stocks mentioned: PHUN, SEAS, SIX, TPR
11 months ago - Forbes

The Applied Genetic Technologies (AGTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Applied Genetic Technologies (AGTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

11 months ago - Zacks Investment Research

Is (AGTC) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

Applied Genetic Reports Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

11 months ago - Seeking Alpha

 -  Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an anima...

11 months ago - GlobeNewsWire

About AGTC

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. I... [Read more...]

Industry
Biotechnology
IPO Date
Mar 27, 2014
CEO
Susan Washer
Employees
83
Stock Exchange
NASDAQ
Ticker Symbol
AGTC
Full Company Profile

Financial Performance

In 2020, AGTC's revenue was $2.45 million, a decrease of -94.12% compared to the previous year's $41.69 million. Losses were -$45.89 million, 2,187.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for AGTC stock is "Strong Buy." The 12-month stock price forecast is 16.38, which is an increase of 329.92% from the latest price.

Price Target
$16.38
(329.92% upside)
Analyst Consensus: Strong Buy